
|Videos|September 14, 2016
The Future of XMT-1536 in Ovarian Cancer and NSCLC
Author(s)Don Bergstrom
Don Bergstrom, MD, PhD, chief medical officer, Mersana Therapeutics, discusses the future of XMT-1536 in the treatment of ovarian cancer and non-small cell lung cancer (NSCLC).
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Improving Survival, Quality of Life, and Cost-Effectiveness for Allo-HCT
2
FDA Approves SimpleScreen Blood Test for CRC Screening
3
Monthly IVIG Lowers Recurrent Infection Rates in Patients With CLL
4
Dato-DXd Plus Pembrolizumab Elicits Responses Even With Low PD-L1
5


























